Colony-Stimulating Factors: a New Step in Clinical Practice. Part II

References

• Nemunaitis J, Meyers J D., Buckner C D., et al. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 1991; 78: 907–13
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Singer J W. Macrophage colony-stimulating factor (M-CSF) biology and clinical applications. High-dose cancer therapy., J Armitage, K Atmann. Williams & Wilkins, Baltimore 1992; 344–361
   Google Scholar
• Khwaja A, Johnson B, Addison I E., et al. In vivo, effects of macrophage colony-stimulating factor on human monocyte function. Br J Haematol 1991; 77: 25–31
   PubMed Web of Science ®Google Scholar
• Garnick M B., Stoudemire J B. Preclinical and clinical evaluation of recombinant human macrophage colonystimulating factor (rhM-CSF). Int J Cell Cloning 1990; 8: 356–73
   PubMedGoogle Scholar
• Hume D A., et al. The therapeutic effect of human recombinant M-CSF in experimental murine metastatic melanoma. Lymphokine Res 1989; 8((1))69–77
   PubMedGoogle Scholar
• Lopez A F., To L B., Yang Y, Gamble J R., et al. Stimulation of proliferation, differentiation, and function of human cells by primate interleukin 3. Proc Natl Acad Sci USA 1987; 84: 2761–5
   PubMed Web of Science ®Google Scholar
• Takaue Y, Kawano Y, Reading C L., Watanabe T. Effects of recombinant human G-CSF, GM-CSF, IL-3, and IL-1α on the growth of purified human peripheral blood progenitors. Blood 1990; 76(2)330–5
   PubMedGoogle Scholar
• Ottman O G., Ganser A, Seipelt G, Eder M, Schulz G, Hoelzer D. Effects of recombinant human interleukin-3 on human hematopoietic progenitor and precursor cells in vivo. Blood 1990; 76(8)1494–1502
   PubMedGoogle Scholar
• Ganser A, Lindemann A, Seipelt G, Ottmann O G., et al. Effects of recombinant human interleukin-3 in aplastic anemia. Blood 1990; 76(7)1–6
   PubMedGoogle Scholar
• Ganser A, Seipelt G, Llndemann A, et al. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 1990; 76: 455–62
   PubMed Web of Science ®Google Scholar
• Oster W, Schultz G. Interleukin-3: biological and clinical effects. Int J Cell Cloning 1991; 9: 5–23
   PubMedGoogle Scholar
• Kurzrock R, Estrov Z, Talpaz M, Gutterman J U. Interleukin-3. Am J Clin Oncol 1991; 14(Suppl 1)S45–S50
   PubMedGoogle Scholar
• Llndemann A, Ganser A, Herrmann F, Frisch J, et al. Biologic effects of recombinant human interleukin-3 in vivo. J Clin Oncol 1991; 9(12)2120–7
   PubMedGoogle Scholar
• Masuda A, et al. Induction of mitochondrial manganese superoxide dismutase by interleukin-1. FASEB 1988; 2: 3087–91
   PubMed Web of Science ®Google Scholar
• Goldstein I M., . Ceruloplasmin: An acute phase reactant and antioxidant. Lymphokines, E Pick, et al. Academic Press, New York 1983; 8: 383
   Google Scholar
• Karin M R., et al. lnterleukin-1 regulates human metallothionein gene expression. Mol Cell Biol 1985; 5: 2866
   PubMed Web of Science ®Google Scholar
• Thornalley P J., et al. Possible role for metallothionein in protection against radiation induced oxidative stress: kinetics and mechanism of its reaction with superoxide and hydroxy radicals. Biochim Biophys Acta 1985; 827: 36
   PubMed Web of Science ®Google Scholar
• Fetkau A. Role of superoxide dismutase in modification of radiation injury. Br J Cancer 1987; 55: 87
   Google Scholar
• Brown J M., White C W., Terada L S., Grosso M A. Interleukin 1 pretreatment decreases ischemia/reperfusion injury. Proc Natl Acad Sci USA 1990; 87: 5026–30
   PubMedGoogle Scholar
• Niwa Y. Lipid peroxides and superoxide dismutase (SOD) induction in skin inflammatory diseases, and treatment with SOD preparations. Dermatologica 1989; 179(Suppl 1)101–6
   PubMedGoogle Scholar
• Lynch D H., Rubin A S., Miller R E., Williams D E. Protective effects of rhulL-1α in normal and tumor-bearing mice treated with doxorubicin. AAI FASEB Meeting, Anaheim, CA 5-9 April, 1992
   Google Scholar
• Dinarello C, Cannon J, Miler J, et al. Multiple biological activities of human recombinant interleukin-1. J Clin Invest 1986; 77: 1734–9
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Andrews D F., Crittenden C, et al. Response of simian virus 40 (SV40) transformed, cultured human stromal cells to hematopoietic growth factors. J Clin Invest 1989; 83: 593–601
   PubMed Web of Science ®Google Scholar
• Rennlck D, Yang G, Gemmell L. Control of hemapoiesis by a bone marrow stromal cell clone: lipopolysaccharide and interleukin-1-inducible production of colony-stimulating factors. Blood 1987; 69: 682–91
   PubMedGoogle Scholar
• Stanley E R., Bartocci A, Patinkin D. Regulation of very primitive, multipotent, hemopoietic cells by hemopoietin-1. Cell 1986; 45: 667–74
   PubMed Web of Science ®Google Scholar
• Moore M AS, et al. Hematologic effects of interleukin-1 β, granulocyte colony-stimulating factor, and granulocyte-macrophage stimulating factor in tumor-bearing mice treated with fluorouracil. J Natl Cancer Inst 1990; 82: 1031–7
   PubMed Web of Science ®Google Scholar
• Oppenhelm J J., Neta R, Tiberghien P, Gress R, Kenny J J., Longo D L. lnterleukin-1 enhances survival of lethally irradiated mice treated with allogeneic bone marrow cells. Blood 1989; 74(6)2257–63
   PubMedGoogle Scholar
• Blumenthal R D., Sharkey R M., Goldenberg D M. Dose escalation of radioantibody in a mouse model with the use of recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor intervention to reduce myelosuppression. J Natl Cancer Inst 1992; 84: 399–407
   PubMedGoogle Scholar
• Castelli M P., Black P L., Schneider M, Pennington R, Fuminori A, Talmadge J E. Protective, restorative, and therapeutic properties of recombinant human IL-1 in rodent models. J Immunol 1988; 140: 3830–7
   PubMed Web of Science ®Google Scholar
• Starnes H F. Biological effects and possible clinical applications of interleukin-1. Semin Hematol 1991; 28: 34–41
   PubMed Web of Science ®Google Scholar
• Suda T, Yamaguchi Y, Suda J, Miura Y, Odano A, Akiyama Y. Effect of interleukin 6 (IL-6) on the differentiation and proliferation of murine and human hemopoietic progenitors. Exp Hematol 1988; 16: 891–5
   PubMed Web of Science ®Google Scholar
• Ishibashi Y, Kimura H, Shikama Y, Uchida T. lnterleukin-6 is a potent thrombopoetic factor in vivo, in mice. Blood 1989; 74: 1241–4
   PubMed Web of Science ®Google Scholar
• Kishumoto T. The biology of interleukin-6. Blood 1989; 74: 1–10
   PubMedGoogle Scholar
• Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol Today 1990; 11: 443–9
   PubMedGoogle Scholar
• Nemunaitis J, Andrews D F., Mochizuki D Y., Lilly M B., Singer J W. Human marrow stromal cells: Response to interleukin-6 (IL-6) and control of IL-6 expression. Blood 1989; 74: 1929–35
   PubMed Web of Science ®Google Scholar
• Dougall W C., Nick H S. Manganese superoxide dismutase: a hepatic acute phase protein regulated by interleukin-6 and glucocorticoids. Endocrinology 1991; 129: 2376–84
   PubMed Web of Science ®Google Scholar
• Williams D E., Park L S., Broxmeyer H E., Lu L. Hybrid cytokines as hematopoietic growth factors. Int J Cell Cloning 1991; 9: 542–7
   PubMedGoogle Scholar
• Williams D E., Eisenmann J, Baird A. Identification of a ligand for the c-kit proto-oncogene. Cell 1990; 63: 167
   PubMed Web of Science ®Google Scholar
• Zsebo K M., Wypych J, McNiece I K. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell 1990; 63: 195
   PubMed Web of Science ®Google Scholar
• Broxmeyer H E., Cooper S, Lu L, Hangoc G, et al. Effect of murine mast cell growth factor (c-kit proto-oncogene Ligand) on colony formation by human marrow hematopoietic progenitor cells. Blood 1991; 77(10)2142–9
   PubMedGoogle Scholar
• McNiece I K., Langley K E., Zsebo K M. Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and EPO to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp Hematol 1991; 19: 226–31
   PubMed Web of Science ®Google Scholar
• Nemunaitis J. A rush on 'stem cell factor': Is it or isn't it?. Exp Hematol 1991; 19: 997
   PubMed Web of Science ®Google Scholar
• Bianco J A., Appelbaum F R., Nemunaitis J, Almgren J, Andres F, Kettner P, Shields A, Singer J W. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991; 78: 1205–11
   PubMed Web of Science ®Google Scholar
• Raines M A., Liu L, Quan S G., Joe V, DiPersio J F., Golde D W. Identification and molecular cloning of a soluble human granulocyte-macrophage colony-stimulating factor receptor. Proc Natl Acad Sci USA 1991; 88: 8203–7
   PubMed Web of Science ®Google Scholar
• Downing J R., Roussel M F., Sherr C J. Ligand and protein kinase C downmodulate the colony-stimulating factor 1 receptor by independent mechanisms. Mol Cell Biol 1989; 9: 2890–6
   PubMed Web of Science ®Google Scholar
• Gray P W., Barrett K, Chantry D, Turner M, Feldmann M. Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein. Proc Natl Acad Sci USA 1990; 87: 7380–4
   PubMed Web of Science ®Google Scholar
• Novick D, Engelmann H, Wallach D, Leltner O, Revel M, Rubinstein M. Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography. J Chromatogr 1990; 510: 331–7
   PubMed Web of Science ®Google Scholar
• Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, et al. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood 1991; 78: 1476–84
   PubMed Web of Science ®Google Scholar
• Kessinger A, Armitage J O., Smith D M., Landmark J D., Bierman P J., Weisenburger D D. High dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989; 74: 1260–5
   PubMed Web of Science ®Google Scholar
• Koerbling K, Holle R, Haas R, Kanuf W, Doerken B, Ho A D., et al. Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site. J Clin Oncol 1990; 8: 978–85
   PubMed Web of Science ®Google Scholar
• Juttner C A., To L B., Haylock D N., Dyson P G., Thorp D, Dart G W., et al. Autologous blood stem-cell transplantation. Transpl Proc 1989; 21: 2929–31
   PubMed Web of Science ®Google Scholar
• Singer J W., Nemunaitis J. Use of recombinant growth factors in bone marrow transplantation. Bone Marrow Transplantation, S J. Forman, E D. Thomas, K G. Blume, (in press)
   Google Scholar
• Socinski M A., Cannistra S A., Ellas A, Antman K H., Schnipper L, Griffin J D. Original articles: Granulocyte-macrophage colony-stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; i: 1194–8
   Google Scholar
• Gianni A M., Bregni M, Stern A C., Siena S, Tarella C, Piler A, Bonnadonna G. Granulocyte-macrophage colonystimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; ii: 580–5
   Google Scholar
• Donahue R E., Seehra J, Metzger M, et al. Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 1988; 241: 1820–2
   PubMed Web of Science ®Google Scholar
• Krumwieth D, Seiler F R. In vivo, effects of recombinant colony stimulating factors on hematopoiesis in cynomolgus monkeys. Transpl Proc 1989; 21: 2964–7
   PubMedGoogle Scholar
• Nemunaitis J. Granulocyte-macrophage colony-stimulating factor: a review from the preclinical development to clinical application. Transfusion, (in press)
   Google Scholar